Skip to main
FULC

FULC Stock Forecast & Price Target

FULC Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 0%
Buy 22%
Hold 56%
Sell 22%
Strong Sell 0%

Bulls say

Fulcrum Therapeutics is facing risks in regards to clinical, regulatory, and financial matters, as unpredicted issues may arise. However, the company may see potential upside from strategic alternative plans that could add value or unexpected regulatory flexibility. Despite discontinuing the development of pociredir for SCD due to concerns of potential secondary hematologic malignancies, Fulcrum plans to review strategic alternatives and reduce operating expenses to preserve capital and extend cash runway. As of 1Q:26, Fulcrum had $333.3 million in cash.

Bears say

Fulcrum Therapeutics is facing challenges in its development of pociredir for sickle cell disease, causing the company to discontinue the program and undergo a strategic review and restructuring. This unexpected setback, combined with the potential for future clinical and regulatory risks, lead to a negative outlook for the company and a recommendation to hold the stock. Additionally, the company may require additional capital to continue its operations.

FULC has been analyzed by 9 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 22% recommend Buy, 56% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fulcrum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fulcrum Therapeutics Inc (FULC) Forecast

Analysts have given FULC a Hold based on their latest research and market trends.

According to 9 analysts, FULC has a Hold consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fulcrum Therapeutics Inc (FULC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.